Prime Medicine Inc (NASDAQ: PRME) kicked off on Friday, up 4.13% from the previous trading day, before settling in for the closing price of $2.42. Over the past 52 weeks, PRME has traded in a range of $2.25-$9.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. While this was happening, its average annual earnings per share was recorded 25.53%. With a float of $51.92 million, this company’s outstanding shares have now reached $131.16 million.
The firm has a total of 214 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.55%, operating margin of -496.77%, and the pretax margin is -480.61%.
Prime Medicine Inc (PRME) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 60.42%, while institutional ownership is 31.12%.
Prime Medicine Inc (PRME) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 25.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.44% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Take a look at Prime Medicine Inc’s (PRME) current performance indicators. Last quarter, stock had a quick ratio of 5.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 110.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 0.96 million was lower than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 8.05%. Additionally, its Average True Range was 0.26.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 10.98%, which indicates a significant decrease from 24.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.47% in the past 14 days, which was higher than the 82.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.84, while its 200-day Moving Average is $4.26. Now, the first resistance to watch is $2.60. This is followed by the second major resistance level at $2.69. The third major resistance level sits at $2.82. If the price goes on to break the first support level at $2.38, it is likely to go to the next support level at $2.25. Now, if the price goes above the second support level, the third support stands at $2.16.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
The company with the Market Capitalisation of 330.53 million has total of 131,161K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -198,130 K annual income. Company’s last quarter sales were recorded 210 K and last quarter income was -52,520 K.
